87 results on '"Frankel, Stanley R."'
Search Results
2. Targeting T cells to tumor cells using bispecific antibodies
3. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
4. Carbonic Anhydrase is Aberrantly and Constitutively Expressed in Both Human and Murine Erythroleukemia Cells
5. Reverse Transcription Polymerase Chain Reaction for the Rearranged Retinoic Acid Receptor α Clarifies Diagnosis and Detects Minimal Residual Disease in Acute Promyelocytic Leukemia
6. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
7. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
8. Pretransplantation Consolidation Chemotherapy Decreases Leukemia Relapse after Autologous Blood and Bone Marrow Transplants for Acute Myelogenous Leukemia in First Remission
9. Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia
10. Polymorphisms in FcγRIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenströmʼs Macroglobulinemia
11. Pentostatin and Cyclophosphamide: An Effective New Regimen in Previously Treated Patients With Chronic Lymphocytic Leukemia
12. Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311
13. United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
14. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia
15. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy
16. All-trans Retinoic Acid for Acute Promyelocytic Leukemia: Results of the New York Study
17. Correction: Location Of bcl-2 Oncogene
18. The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia
19. Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)
20. Prospective Karyotype Analysis in Adult Acute Lymphoblastic Leukemia: The Cancer and Leukemia Group B Experience
21. Value of Immunophenotype in Intensively Treated Adult Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8364
22. Reversible Tacrolimus-induced Neurotoxicity Isolated to the Brain Stem
23. The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.
24. Target discovery for T cell therapy: next steps to advance Immunotherapies.
25. PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells
26. Current approaches to acute promyelocytic leukemia.
27. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.
28. Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia: Case report and review of literature.
29. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia.
30. Effects of graded hypoxia on contraction of cultured chick embryo ventricular cells.
31. Giant Cell Vasculitis with Extravascular Granulomas in an Adolescent.
32. Long Term Responses to Fludarabine and Rituximab in Waldenstrom's Macroglobulinemia
33. The Power and Perils of Prediction.
34. Clinical Responses to Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Are Associated with Specific Gene Expression Signatures in Patients with Advanced Leukemias: Results of a Phase I Trial.
35. Identification of Informative Gene Expression Signatures Indicative of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Exposure and Clinical Efficacy in Patients with Advanced Cutaneous T-Cell Lymphoma.
36. High Expression and Persistent Activation of STAT1, 3 and 5 Predicts Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Resistance in Cutaneous T-Cell Lymphoma Cells.
37. Effective Asparagine Depletion with Pegylated Asparaginase Results in Improved Outcomes in Adult Acute Lymphoblastic Leukemia (ALL) — Cancer and Leukemia Group B Study 9511.
38. Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B.
39. Expression of Carbonic Anhydrase and Globin during Erythropoiesis in Vitro.
40. High Dose Cytosine Arabinoside, Idarubicin and G-CSF Therapy for De Novo and Secondary Adult Acute Myeloid Leukemia.
41. Phase 2 Study of Oblimersen Sodium (G3139; Bcl-2 Antisense; Genasense®) Plus Gemtuzumab Ozogamcin (Mylotarg®) in Elderly Patients with Relapsed Acute Myeloid Leukemia (AML).
42. Combination Therapy with Rituximab and Fludarabine in Waldenstrom's Macroglobulinemia.
43. Novel Retinoic Acid Receptor-α Transcripts in Acute Promyelocytic Leukemia Responsive to All-trans-Retinoic Acid.
44. Phase I trial of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with solid tumors.
45. A Randomized Controlled Trial of Filgrastim During Remission Induction and Consolidation Chemotherapy for Adults With Acute Lymphoblastic Leukemia: CALGB Study 9111
46. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.
47. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
48. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.
49. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
50. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.